Liver Changes and EBV Reactivation: A Rare Side Effect Observed During Teplizumab Treatment
Researchers reported a case of temporary liver enzyme elevation and Epstein-Barr virus reactivation in a teenager receiving teplizumab for early-stage Type 1 diabetes. The condition resolved on its own, but the findings add to what we know about how this immunotherapy affects the body.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- A 15-year-old with stage 2 Type 1 diabetes developed elevated liver enzymes after completing a standard course of teplizumab, with levels peaking about a week after treatment ended
- Epstein-Barr virus (EBV) DNA was detected in the patient's blood during the same period, suggesting possible viral reactivation linked to immune changes from the drug
- All liver abnormalities and elevated enzymes resolved naturally over several months without specific treatment
- This appears to be a rare occurrence; it does not represent a known common side effect of teplizumab
- This case report highlights the importance of monitoring patients receiving teplizumab and informs our understanding of how the drug interacts with the immune system
What Happened in This Case
A 15-year-old boy with stage 2 Type 1 diabetes completed a standard course of teplizumab infusions. During treatment, his liver enzyme levels—specifically ALT and AST—rose slightly but remained only mildly elevated. However, after the infusions ended, his liver enzymes climbed much higher. On the fifth day after treatment finished, his ALT reached 292 U/L and AST reached 172 U/L (both roughly 7 times the upper normal limit). The levels peaked the next day, then improved somewhat before rising again around day 20 of follow-up.
Importantly, other markers of liver function—bilirubin and coagulation parameters—stayed normal throughout. An ultrasound and MRI of the abdomen showed only minor, nonspecific changes that improved on repeat imaging.
Investigating the Cause: EBV Reactivation
Doctors ordered extensive testing to rule out other causes of liver injury, including autoimmune hepatitis, hepatitis B and C, and several viral infections. All of these tests came back negative. However, testing revealed something notable: Epstein-Barr virus (EBV) DNA was detected in the patient's blood at very high levels (over 500,000 copies per milliliter) about 10 days after treatment ended.
The patient had evidence of past EBV infection before teplizumab (positive VCA IgG antibody), but the sudden spike in EBV DNA in the blood suggests the virus reactivated—likely because teplizumab's effects on the immune system allowed dormant virus to multiply. The EBV DNA gradually decreased over the following months and became undetectable.
Whether the liver enzyme elevation was directly caused by EBV reactivation, by teplizumab itself, or by both working together remains unclear. This is why the research team titled their report as a question: 'drug-induced liver injury, viral reactivation, or both?'
What the Case Shows Us
This report documents a rare but real side effect that occurred in one patient receiving teplizumab. The findings add to a growing understanding that teplizumab can cause laboratory abnormalities and may trigger reactivation of viruses like EBV that remain dormant in people who have been infected before.
The good news: the patient's liver enzymes normalized completely without any special treatment, and all abnormalities resolved during routine follow-up. The case does not indicate that these effects are common or that they prevent the use of teplizumab in eligible patients.
The case does underscore why medical teams monitor patients carefully during and after teplizumab treatment, watching for signs of liver changes or unexpected infections. It also highlights an area where more research may be needed to understand exactly how teplizumab affects immune control of latent viruses.
Evidence label
Source: Frontiers in endocrinology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
From Type1Cure
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Research summaryCauses & What We KnowPregnant Women with Diabetes Show Higher Rates of Toxoplasma InfectionPubMed indexed literature
- Research summaryCauses & What We KnowExploring Rare Breast Inflammation: What BRCA Mutations and Type 1 Diabetes May SharePubMed indexed literature
- Research summaryCauses & What We KnowUnderstanding Type 1 Diabetes: A Shift Toward Early InterventionPubMed indexed literature
- Research summaryCauses & What We KnowHow Nutrition, Metabolism, and Immunity Connect: What the Lectin Pathway Tells UsPubMed indexed literature
- Research summaryCauses & What We KnowHow Gut Bacteria May Influence the Intestinal Barrier in Type 1 DiabetesPubMed indexed literature
- Research summaryCauses & What We KnowLiver Changes in Cystic Fibrosis: What a New Study FoundPubMed indexed literature